MeiraGTx Holdings (MGTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

MeiraGTx Holdings

NasdaqGS•Healthcare•Biotechnology

$12.79-0.06(<0.01%)Pre-market

Market Cap

$1.21B

P/E

15.3x

P/S

3.0x

P/B

5.6x

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

How this company scores

ExcellentMetricSide Score: 81/100

Strongest: Profitability (25/25); weakest: Cash & Earnings Quality (13/25).

Profitability25/25

Growth22/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality13/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 15.3x5y range 15.3x – 15.3x

P/S · 3.0x5y range 3.0x – 57.2x

Currently below its 20-quarter median.

P/B · 5.6x5y range 2.4x – 177.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.21B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $397.50M
Q. Revenue: $321.43M
TTM EBITDA: $196.13M
TTM Op. Income: $184.03M
Q. Op. Income: $244.43M
TTM Net Income: $78.98M
Q. Net Income: $160.72M
EPS: $1.76
Shares Out.: $91.42M

$397.50M in TTM revenue grew 948.3% YoY, reaching $321.43M last quarter. TTM EBITDA of $196.13M and TTM operating income of $184.03M show growth is flowing through to the bottom line. TTM net income of $78.98M means revenue is converting into profit. Over the past year, TTM revenue is up 948% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 76.9%
Op. Margin: 76.0%
Net Margin: 50.0%

Op. margin of 76.0% is up 1289.6% YoY — cost efficiency is improving. Net margin at 50.0% Over the past year, operating margin is up 106% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 15.3x
P/S Ratio: 3.0x
P/B Ratio: 5.6x

At 15.3x P/E, the stock trades within typical market levels. P/S of 3.0x and P/B of 5.6x provide additional context. Use the growth and margin sections to judge whether the multiple is justified.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $396.45M
Cash: $143.17M
Long-Term Debt: $100.00M
Book Value: $215.78M
D/E Ratio: 0.5
Debt/EBITDA: 0.4

With $396.45M in assets and $100.00M in long-term debt, D/E is 0.5and book value is $215.78M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 39% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-38.54M
TTM Free Cash Flow: $10.47M
FCF Margin: 2.6%
FCF / Net Income: 0.1

TTM FCF of $10.47M on $-38.54M in operating cash flow. The FCF / Net Income ratio of 0.1x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.